Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics, a biopharmaceutical company focused on patient care, has recently received protocol approval for its cancer therapeutic, HT-001. This exciting development was announced on July 19, 2023. &nbsp The FDA-approved trial now has two sites approved for conducting the study, and additional sites are currently in the approval process. This means that recruitment of patients can now be..